1. Home
  2. PAYP vs TGTX Comparison

PAYP vs TGTX Comparison

Compare PAYP & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PayPay Corporation American Depository Shares

PAYP

PayPay Corporation American Depository Shares

N/A

Current Price

$14.62

Market Cap

9.4B

Sector

Real Estate

ML Signal

N/A

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$52.45

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAYP
TGTX
Founded
2018
1993
Country
Japan
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.4B
8.5B
IPO Year
2026
2008

Fundamental Metrics

Financial Performance
Metric
PAYP
TGTX
Price
$14.62
$52.45
Analyst Decision
Buy
Strong Buy
Analyst Count
9
5
Target Price
$25.54
$49.80
AVG Volume (30 Days)
1.5M
2.8M
Earning Date
08-12-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1746.67
EPS
N/A
0.12
Revenue
N/A
$2,785,000.00
Revenue This Year
N/A
$49.08
Revenue Next Year
$20.92
$26.69
P/E Ratio
N/A
$444.67
Revenue Growth
N/A
N/A
52 Week Low
$12.07
$25.37
52 Week High
$24.89
$57.38

Technical Indicators

Market Signals
Indicator
PAYP
TGTX
Relative Strength Index (RSI) 43.82 65.01
Support Level $12.07 $28.57
Resistance Level $23.11 $57.38
Average True Range (ATR) 0.99 2.42
MACD 0.30 -0.13
Stochastic Oscillator 79.31 49.59

Price Performance

Historical Comparison
PAYP
TGTX

About PAYP PayPay Corporation American Depository Shares

PayPay is a fintech company jointly owned by Softbank and LY. It was founded in 2018, following the success of Alipay and WeChat Pay in China, and was the pioneering code payment app in Japan. Over the past seven years, it has amassed more than 70 million users and is the market leader in code payments.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: